HCC CONNECT has summarised the highlights of EASL 2017 for you.


The changing landscape in the treatment of HCC by Dr. Jean-Charles Nault

 

Jean-Charles Nault received his MD and PhD from Paris Descartes University. He is currently working in the liver unit of the Jean Verdier Hospital in Bondy, France with a high priority on early detection of primary liver tumors and on therapeutic innovation. He is also an active member of the Laboratory of Functional Genomics of Solid Tumours at the INSERM UMR 1162 headed by Professor Jessica-Zucman Rossi. His research is dedicated to translational research in particular the identification of new driver genes in hepatocellular adenoma and hepatocellular carcinoma, of new therapeutic targets and of the molecular determinants of hepatocellular carcinoma’s prognosis. Relevant publications Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP investigators., Bioulac-Sage P, Letouzé E, Zucman-Rossi J. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 2016 Dec 7. Nault JC. The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma. Lancet 2017 Jan 7; 389(10064): 4-6. Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015 Oct; 47(10): 1187-93. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M, Zucman-Rossi J. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014 Dec; 60(6): 1983-92. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Balabaud C, Zucman-Rossi J. High frequency of TERT promoter mutations in hepatocellular carcinoma and pre-neoplastic lesions. Nat Commun 2013; 4: 2218. doi: 10.1038/ncomms3218. Nault JC, de Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J. A hepatocellular carcinoma 5-gene score associated with survival of patients following liver resection. Gastroenterology 2013 Jul; 145(1): 176-87. doi: 10.1053/j.gastro.2013.03.051. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013 Feb; 144(5): 888-902. doi: 10.1053/j.gastro.2013.02.032. Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, Salenave S, Balabaud C, Prevot S, Labrune P, Bioulac-Sage P, Scoazec JY, Chanson P, Zucman-Rossi J. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 2012 Jan; 56(1): 184-91.

Programme summary
Watch the video now
Other episodes of this series
HCC CONNECT Update from EASL 2017

HCC CONNECT Update from EASL 2017

Episode 2 Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

micro-learning Micro learning - Video, slides and more

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning - Video, slides and more

Module

3

of 4

module
Oncology 
The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC

Experts
Prof. Aiwu Ruth He, Prof. Beau Toskich
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Apr 2025
  • Non-accredited Independent Medical Education

AstraZeneca has provided a sponsorship grant towards this independent programme.
podcast Video podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jan 2025
  • Non-accredited Independent Medical Education

AstraZeneca has provided a sponsorship grant towards this independent programme.
podcast Video podcast

Episode

3

of 4

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast

Episode

2

of 4

episode
Oncology 
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Medical experts discuss how to approach sequencing in clinical practice

Experts
Prof. Arndt Vogel, Assoc. Prof. Lorenza Rimassa, Oncology Brothers (Moderators)
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education